A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: LMWH

  • Pregnancy, Breastfeeding – Safety of Various Anticoagulants

    Stephan Moll, MD writes… LMWH (low molecular weight heparin) is the preferred anticoagulant in the pregnant patient. LMWH and warfarin are safe in the woman who is beast-feeding. Rivaroxaban (Xarelto), dabigatran (Pradaxa) and apixaban (Eliquis) should not be used during pregnancy or while breastfeeding. A detailed summary about the safety of the various anticoagulants during pregnancy…

  • LMWH and Epidural Catheters – FDA Recommendations

    Stephan Moll, MD writes… The FDA published today a drug safety recommendation to decrease bleeding and paralysis risk for patients receiving epidural catheters and being treated with LMWH  (detailed FDA report is here).  While in many parts of the document the FDA talks specifically about enoxaparin, the communication states that “these new timing recommendations….. will be added to the…

  • LMWH Injections – Making it Easier: Insuflon Ports

    Once or twice daily injections of s.c. anticoagulants for prolonged periods of time can be bothersome and unacceptable for the patient. Use of a once weekly exchanged s.c. port, called Insuflon, can make longer-term s.c. anticoagulant therapy easier and more tolerable.

  • Pregnancy Loss and Thrombophilia

    How common is pregnancy loss? What are the causes? Pregnancy loss  in the general population is common. Most losses occur in the first trimester. As many as 5 % of women have 2 or more early losses; 1-2 % have 3 or more early losses [ref 1]. Well established risk factors for pregnancy loss are:…

  • Low Molecular Weight Heparins – Osteoporosis?

    Occasionally, a patient is treated with long-term low molecular weight heparin (LMWH) (enoxaparin = Lovenox®; Dalteparin = Fragmin®; Tinzaparin = Innohep®) . LMWH may be given because the patient (a) tolerated warfarin poorly (widely fluctuating INRs; significant side-effects, such as marked hair loss or fatigue), (b) had a recurrent thrombotic event which occured with a therapeutic INR, or…